

*Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meanings as those defined in the prospectus (the “**Prospectus**”) of Better Medical Investment Holdings Limited (the “**Company**”) dated 22 September 2022.*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an invitation or offer by any person to acquire, purchase or subscribe for any Shares or other securities of the Company. Potential investors should read the Prospectus carefully for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered.

*This announcement is not for release, publication, distribution, directly or indirectly in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities of the Company in the United States or in any other jurisdictions or an invitation to engage in any investment activity with respect to securities or investments of any kind. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any state securities laws of the United States, and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (the “**Regulation S**”)) except in transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There has not been and it is not currently intended to be any public offer of securities in the United States.*

The Joint Global Coordinators confirm that there has been no over-allocation of the Shares under the International Placing. Therefore, the Stock Borrowing Agreement will not be entered into and the Over-allotment Option will not be exercised. In view of the fact there has been no over-allocation in the International Placing, no stabilising action will be taken during the stabilisation period.

Potential investors of the Offer Shares should note that the Joint Global Coordinators shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date.

Unless otherwise specified, all dates and time in this announcement refer to Hong Kong dates and time.



Betters Medical Investment Holdings Limited
百德医疗投资控股有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	248,000,000 Shares
Number of Hong Kong Offer Shares	:	45,080,000 Shares (as adjusted after reallocation)
Number of International Placing Shares	:	202,920,000 Shares (as adjusted after reallocation)
Final Offer Price	:	HK\$1.40 per Offer Share, excluding brokerage of 1.00%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%
Nominal value	:	HK\$0.01 per Share
Stock code	:	6678

Joint Sponsors



Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers

